InCarda Therapeutics is at the forefront of developing innovative therapies for cardiovascular conditions, specifically focusing on the inhalation route for drug delivery. Their lead product candidate, orally inhaled flecainide, is designed to treat paroxysmal atrial fibrillation (PAF) by rapidly delivering the antiarrhythmic agent flecainide directly to the heart via the lungs. This novel nebulization therapy aims to restore normal sinus rhythm quickly, alleviating symptoms associated with acute PAF episodes. The company envisions that this approach will not only provide a safe and effective treatment option but also empower patients to manage their condition independently in various settings, including at home.

The technology behind InCarda's inhaled flecainide leverages a high-performance drug delivery platform that utilizes a vibrating-mesh aerosol generation engine. This system is designed to optimize the inhalation process, ensuring efficient delivery of the medication to the deep lungs for rapid systemic absorption. Preliminary clinical studies have shown promising results, indicating that inhaled flecainide can achieve effective plasma concentrations with a lower drug dose, potentially minimizing side effects. InCarda's approach represents a significant advancement in the management of PAF, addressing a critical unmet need for rapid-acting treatments that can be self-administered by patients during acute episodes.

United States

InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route.  The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF).

InCarda Therapeutics

Company Details